Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial - Concepedia

Concepedia

Publication | Closed Access

Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

349

Citations

21

References

2021

Year

Aditya Bardia, Wells A. Messersmith, Ebenezer A. Kio, Jordan Berlin, Linda T. Vahdat, Gregory A. Masters, R Moroose, Alessandro D. Santin, Kevin Kalinsky, Vincent J. Picozzi,

Annals of Oncology

References

	Year	Citations

Page 1